{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:09:33Z","timestamp":1794316173509,"version":"4.9.0"},"reference-count":207,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Special Foundation Projects of Joint Applied Basic Research of Yunnan Provincial Department of Science and Technology with Kunming Medical University","award":["202301AY070001-119"],"award-info":[{"award-number":["202301AY070001-119"]}]},{"name":"Natural Science Foundation","award":["82270372"],"award-info":[{"award-number":["82270372"]}]},{"name":"Program Innovative Research Team in Science and Technology in Kunming Medical University","award":["CXTD202202"],"award-info":[{"award-number":["CXTD202202"]}]},{"name":"Yunnan Health Training Project of High-Level Talents","award":["H-2019052"],"award-info":[{"award-number":["H-2019052"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diabetic heart disease (DHD) is a serious complication in patients with diabetes. Despite numerous studies on the pathogenic mechanisms and therapeutic targets of DHD, effective means of prevention and treatment are still lacking. The pathogenic mechanisms of DHD include cardiac inflammation, insulin resistance, myocardial fibrosis, and oxidative stress. Macrophages, the primary cells of the human innate immune system, contribute significantly to these pathological processes, playing an important role in human disease and health. Therefore, drugs targeting macrophages hold great promise for the treatment of DHD. In this review, we examine how macrophages contribute to the development of DHD and which drugs could potentially be used to target macrophages in the treatment of DHD.<\/jats:p>","DOI":"10.1186\/s12933-024-02273-4","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T12:01:48Z","timestamp":1715774508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Therapeutic strategies targeting mechanisms of macrophages in diabetic heart disease"],"prefix":"10.1186","volume":"23","author":[{"given":"Chaoyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunke","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivon Mirza","family":"Sudesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"2273_CR1","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, et al. Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"2273_CR2","doi-asserted-by":"crossref","unstructured":"Standards of medical care in diabetes\u20132014 Diabetes Care, 2014. 37 Suppl 1: pp. S14-80.","DOI":"10.2337\/dc14-S014"},{"issue":"9","key":"2273_CR3","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.2337\/diacare.24.9.1614","volume":"24","author":"GA Nichols","year":"2001","unstructured":"Nichols GA, et al. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24(9):1614\u20139.","journal-title":"Diabetes Care"},{"issue":"2","key":"2273_CR4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jchf.2014.08.004","volume":"3","author":"A Dei Cas","year":"2015","unstructured":"Dei Cas A, et al. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail. 2015;3(2):136\u201345.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"2273_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-018-4711-2","volume":"62","author":"JL Harding","year":"2019","unstructured":"Harding JL, et al. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62(1):3\u201316.","journal-title":"Diabetologia"},{"key":"2273_CR6","doi-asserted-by":"crossref","first-page":"175720","DOI":"10.1016\/j.ejphar.2023.175720","volume":"949","author":"D Dasari","year":"2023","unstructured":"Dasari D, et al. Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function. Eur J Pharmacol. 2023;949:175720.","journal-title":"Eur J Pharmacol"},{"key":"2273_CR7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2147\/DDDT.S400249","volume":"17","author":"P Fang","year":"2023","unstructured":"Fang P, et al. Glucagon-like peptide-1receptor agonist protects against diabetic cardiomyopathy by modulating microRNA-29b-3p\/SLMAP. Drug Des Devel Ther. 2023;17:791\u2013806.","journal-title":"Drug Des Devel Ther"},{"key":"2273_CR8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3389\/fphys.2020.00425","volume":"11","author":"Z Yang","year":"2020","unstructured":"Yang Z, et al. Metformin ameliorates diabetic cardiomyopathy by activating the PK2\/PKR pathway. Front Physiol. 2020;11:425.","journal-title":"Front Physiol"},{"issue":"11","key":"2273_CR9","first-page":"1501","volume":"126","author":"RH Ritchie","year":"2020","unstructured":"Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. Circ Res. 2020;126(11):1501\u201325.","journal-title":"Basic Mech Diabet Heart Disease Circ Res"},{"issue":"3","key":"2273_CR10","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/cvr\/cvac049","volume":"119","author":"RJ Phang","year":"2023","unstructured":"Phang RJ, et al. Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy. Cardiovasc Res. 2023;119(3):668\u201390.","journal-title":"Cardiovasc Res"},{"issue":"11","key":"2273_CR11","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.tips.2022.04.005","volume":"43","author":"D Prakoso","year":"2022","unstructured":"Prakoso D, et al. Current landscape of preclinical models of diabetic cardiomyopathy. Trends Pharmacol Sci. 2022;43(11):940\u201356.","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"2273_CR12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000177322","volume":"88","author":"E Astorri","year":"1997","unstructured":"Astorri E, et al. Left ventricular function in insulin-dependent and in non-insulin-dependent diabetic patients: radionuclide assessment. Cardiology. 1997;88(2):152\u20135.","journal-title":"Cardiology"},{"issue":"7","key":"2273_CR13","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/dom.13260","volume":"20","author":"T Yamada","year":"2018","unstructured":"Yamada T, et al. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(7):1755\u201361.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2273_CR14","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","volume":"39","author":"C Mathieu","year":"2016","unstructured":"Mathieu C, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE Treat-To-Target Randomized Trial. Diabetes Care. 2016;39(10):1702\u201310.","journal-title":"Diabetes Care"},{"key":"2273_CR15","doi-asserted-by":"crossref","unstructured":"Marx N et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","DOI":"10.1093\/eurheartj\/ehad774"},{"issue":"23","key":"2273_CR16","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1016\/j.cell.2022.10.007","volume":"185","author":"MD Park","year":"2022","unstructured":"Park MD, et al. Macrophages in health and disease. Cell. 2022;185(23):4259\u201379.","journal-title":"Cell"},{"issue":"3","key":"2273_CR17","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI59643","volume":"122","author":"A Sica","year":"2012","unstructured":"Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787\u201395.","journal-title":"J Clin Invest"},{"issue":"3","key":"2273_CR18","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41423-021-00791-9","volume":"19","author":"SK Wculek","year":"2022","unstructured":"Wculek SK, et al. Metabolism of tissue macrophages in homeostasis and pathology. Cell Mol Immunol. 2022;19(3):384\u2013408.","journal-title":"Cell Mol Immunol"},{"key":"2273_CR19","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1100\/2011\/213962","volume":"11","author":"L Cassetta","year":"2011","unstructured":"Cassetta L, Cassol E, Poli G. Macrophage polarization in health and disease. ScientificWorldJournal. 2011;11:2391\u2013402.","journal-title":"ScientificWorldJournal"},{"issue":"1","key":"2273_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00011-015-0874-1","volume":"65","author":"S Bashir","year":"2016","unstructured":"Bashir S, et al. Macrophage polarization: the link between inflammation and related diseases. Inflamm Res. 2016;65(1):1\u201311.","journal-title":"Inflamm Res"},{"issue":"2","key":"2273_CR21","doi-asserted-by":"crossref","first-page":"534","DOI":"10.7150\/ijms.51618","volume":"18","author":"C Peng","year":"2021","unstructured":"Peng C, Li Z, Yu X. The role of pancreatic infiltrating innate immune cells in acute pancreatitis. Int J Med Sci. 2021;18(2):534\u201345.","journal-title":"Int J Med Sci"},{"key":"2273_CR22","doi-asserted-by":"crossref","unstructured":"Sterling KG et al. Mucosal immunity and the Gut-Microbiota-Brain-Axis in Neuroimmune Disease. Int J Mol Sci, 2022. 23(21).","DOI":"10.3390\/ijms232113328"},{"issue":"1","key":"2273_CR23","doi-asserted-by":"crossref","first-page":"2149412","DOI":"10.1080\/0886022X.2022.2149412","volume":"45","author":"Z Hu","year":"2023","unstructured":"Hu Z, et al. Depletion of macrophages with clodronate liposomes partially attenuates renal fibrosis on AKI-CKD transition. Ren Fail. 2023;45(1):2149412.","journal-title":"Ren Fail"},{"key":"2273_CR24","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3389\/fimmu.2015.00602","volume":"6","author":"TT Braga","year":"2015","unstructured":"Braga TT, Agudelo JS, Camara NO. Macrophages during the fibrotic process: M2 as friend and Foe. Front Immunol. 2015;6:602.","journal-title":"Front Immunol"},{"issue":"12","key":"2273_CR25","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","volume":"164","author":"CD Mills","year":"2000","unstructured":"Mills CD, et al. M-1\/M-2 macrophages and the Th1\/Th2 paradigm. J Immunol. 2000;164(12):6166\u201373.","journal-title":"J Immunol"},{"key":"2273_CR26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-012418-012718","volume":"15","author":"M Locati","year":"2020","unstructured":"Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 2020;15:123\u201347.","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"2273_CR27","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1161\/CIRCRESAHA.116.309194","volume":"119","author":"M Nahrendorf","year":"2016","unstructured":"Nahrendorf M, Swirski FK. Abandoning M1\/M2 for a network model of macrophage function. Circ Res. 2016;119(3):414\u20137.","journal-title":"Circ Res"},{"issue":"6","key":"2273_CR28","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2014.11.023","volume":"159","author":"D Gosselin","year":"2014","unstructured":"Gosselin D, et al. Environment drives selection and function of enhancers controlling tissue-specific macrophage identities. Cell. 2014;159(6):1327\u201340.","journal-title":"Cell"},{"issue":"9","key":"2273_CR29","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41569-020-0339-2","volume":"17","author":"Y Tan","year":"2020","unstructured":"Tan Y, et al. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17(9):585\u2013607.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"2273_CR30","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR. Diabetic Cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624\u201338.","journal-title":"Circ Res"},{"issue":"27","key":"2273_CR31","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","volume":"36","author":"PM Seferovi\u0107","year":"2015","unstructured":"Seferovi\u0107 PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36(27):1718\u201327.","journal-title":"Eur Heart J"},{"issue":"3","key":"2273_CR32","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","volume":"71","author":"TH Marwick","year":"2018","unstructured":"Marwick TH, et al. Implications of underlying mechanisms for the Recognition and Management of Diabetic Cardiomyopathy. J Am Coll Cardiol. 2018;71(3):339\u201351.","journal-title":"J Am Coll Cardiol"},{"key":"2273_CR33","doi-asserted-by":"crossref","unstructured":"Lin HT et al. (1)H nuclear magnetic resonance (NMR)-Based cerebrospinal fluid and plasma metabolomic analysis in type 2 Diabetic patients and Risk Prediction for Diabetic Microangiopathy. J Clin Med, 2019. 8(6).","DOI":"10.3390\/jcm8060874"},{"issue":"4","key":"2273_CR34","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.molmed.2019.01.002","volume":"25","author":"M DeBerge","year":"2019","unstructured":"DeBerge M, et al. Macrophages in Heart failure with reduced versus preserved ejection fraction. Trends Mol Med. 2019;25(4):328\u201340.","journal-title":"Trends Mol Med"},{"key":"2273_CR35","first-page":"p732450","volume":"2015","author":"X Jin","year":"2015","unstructured":"Jin X, et al. Advanced Glycation End products enhance macrophages polarization into M1 phenotype through activating RAGE\/NF-\u03baB pathway. Biomed Res Int. 2015;2015:p732450.","journal-title":"Biomed Res Int"},{"key":"2273_CR36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fendo.2017.00072","volume":"8","author":"PK Mishra","year":"2017","unstructured":"Mishra PK, et al. Diabetic Cardiomyopathy: an immunometabolic perspective. Front Endocrinol (Lausanne). 2017;8:72.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2273_CR37","doi-asserted-by":"crossref","unstructured":"Watanabe R et al. Glucose metabolism controls disease-specific signatures of macrophage effector functions. JCI Insight, 2018. 3(20).","DOI":"10.1172\/jci.insight.123047"},{"issue":"6","key":"2273_CR38","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/CIRCRESAHA.119.312321","volume":"126","author":"AJ Mouton","year":"2020","unstructured":"Mouton AJ, et al. Obesity, hypertension, and Cardiac Dysfunction: Novel roles of Immunometabolism in Macrophage activation and inflammation. Circ Res. 2020;126(6):789\u2013806.","journal-title":"Circ Res"},{"key":"2273_CR39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1475-2840-8-58","volume":"8","author":"W Dinh","year":"2009","unstructured":"Dinh W, et al. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc Diabetol. 2009;8:58.","journal-title":"Cardiovasc Diabetol"},{"issue":"81","key":"2273_CR40","doi-asserted-by":"crossref","first-page":"81ps17","DOI":"10.1126\/scitranslmed.3001902","volume":"3","author":"SL Masters","year":"2011","unstructured":"Masters SL, Latz E, O\u2019Neill LA. The inflammasome in atherosclerosis and type 2 diabetes. Sci Transl Med. 2011;3(81):81ps17.","journal-title":"Sci Transl Med"},{"issue":"4","key":"2273_CR41","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/CIRCHEARTFAILURE.114.001963","volume":"8","author":"A Biernacka","year":"2015","unstructured":"Biernacka A, et al. Smad3 Signaling promotes Fibrosis while preserving Cardiac and aortic geometry in obese Diabetic mice. Circ Heart Fail. 2015;8(4):788\u201398.","journal-title":"Circ Heart Fail"},{"key":"2273_CR42","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3389\/fphys.2018.01547","volume":"9","author":"A Bajpai","year":"2018","unstructured":"Bajpai A, Tilley DG. The role of leukocytes in Diabetic Cardiomyopathy. Front Physiol. 2018;9:1547.","journal-title":"Front Physiol"},{"issue":"1","key":"2273_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.0300-9475.2005.01534.x","volume":"61","author":"R Kokkola","year":"2005","unstructured":"Kokkola R, et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol. 2005;61(1):1\u20139.","journal-title":"Scand J Immunol"},{"issue":"2","key":"2273_CR44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1055\/s-0030-1251503","volume":"36","author":"HC Volz","year":"2010","unstructured":"Volz HC, et al. The role of HMGB1\/RAGE in inflammatory cardiomyopathy. Semin Thromb Hemost. 2010;36(2):185\u201394.","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"2273_CR45","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41581-019-0234-4","volume":"16","author":"SCW Tang","year":"2020","unstructured":"Tang SCW, Yiu WH. Innate immunity in diabetic kidney disease. Nat Rev Nephrol. 2020;16(4):206\u201322.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"2273_CR46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1172\/JCI6709","volume":"104","author":"S Frantz","year":"1999","unstructured":"Frantz S, et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999;104(3):271\u201380.","journal-title":"J Clin Invest"},{"key":"2273_CR47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1479-5876-8-133","volume":"8","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, et al. Prevention of hyperglycemia-induced myocardial apoptosis by gene silencing of toll-like receptor-4. J Transl Med. 2010;8:133.","journal-title":"J Transl Med"},{"issue":"6","key":"2273_CR48","doi-asserted-by":"crossref","first-page":"H732","DOI":"10.1152\/ajpheart.00948.2011","volume":"303","author":"B Dong","year":"2012","unstructured":"Dong B, et al. TLR4 regulates cardiac lipid accumulation and diabetic heart disease in the nonobese diabetic mouse model of type 1 diabetes. Am J Physiol Heart Circ Physiol. 2012;303(6):H732\u201342.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"10 Pt A","key":"2273_CR49","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.bbadis.2015.07.015","volume":"1852","author":"A Tao","year":"2015","unstructured":"Tao A, et al. Cardiomyocyte-fibroblast interaction contributes to diabetic cardiomyopathy in mice: role of HMGB1\/TLR4\/IL-33 axis. Biochim Biophys Acta. 2015;1852(10 Pt A):2075\u201385.","journal-title":"Biochim Biophys Acta"},{"key":"2273_CR50","doi-asserted-by":"crossref","first-page":"13997","DOI":"10.1038\/ncomms13997","volume":"8","author":"Y Wang","year":"2017","unstructured":"Wang Y, et al. Saturated palmitic acid induces myocardial inflammatory injuries through direct binding to TLR4 accessory protein MD2. Nat Commun. 2017;8:13997.","journal-title":"Nat Commun"},{"issue":"9","key":"2273_CR51","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1172\/JCI34260","volume":"118","author":"S Schenk","year":"2008","unstructured":"Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest. 2008;118(9):2992\u20133002.","journal-title":"J Clin Invest"},{"issue":"5","key":"2273_CR52","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI25102","volume":"115","author":"KE Wellen","year":"2005","unstructured":"Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115(5):1111\u20139.","journal-title":"J Clin Invest"},{"issue":"12","key":"2273_CR53","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1074\/jbc.275.12.9047","volume":"275","author":"V Aguirre","year":"2000","unstructured":"Aguirre V, et al. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of ser(307). J Biol Chem. 2000;275(12):9047\u201354.","journal-title":"J Biol Chem"},{"issue":"50","key":"2273_CR54","doi-asserted-by":"crossref","first-page":"48115","DOI":"10.1074\/jbc.M209459200","volume":"277","author":"Z Gao","year":"2002","unstructured":"Gao Z, et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem. 2002;277(50):48115\u201321.","journal-title":"J Biol Chem"},{"issue":"5091","key":"2273_CR55","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.7678183","volume":"259","author":"GS Hotamisligil","year":"1993","unstructured":"Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87\u201391.","journal-title":"Science"},{"issue":"12","key":"2273_CR56","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1172\/JCI200319246","volume":"112","author":"SP Weisberg","year":"2003","unstructured":"Weisberg SP, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796\u2013808.","journal-title":"J Clin Invest"},{"issue":"12","key":"2273_CR57","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI200319451","volume":"112","author":"H Xu","year":"2003","unstructured":"Xu H, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821\u201330.","journal-title":"J Clin Invest"},{"key":"2273_CR58","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-physiol-021909-135846","volume":"72","author":"JM Olefsky","year":"2010","unstructured":"Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219\u201346.","journal-title":"Annu Rev Physiol"},{"issue":"4","key":"2273_CR59","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cmet.2008.08.015","volume":"8","author":"D Patsouris","year":"2008","unstructured":"Patsouris D, et al. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 2008;8(4):301\u20139.","journal-title":"Cell Metab"},{"issue":"6","key":"2273_CR60","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1172\/JCI26498","volume":"116","author":"H Kanda","year":"2006","unstructured":"Kanda H, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006;116(6):1494\u2013505.","journal-title":"J Clin Invest"},{"issue":"6651","key":"2273_CR61","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/39335","volume":"389","author":"KT Uysal","year":"1997","unstructured":"Uysal KT, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997;389(6651):610\u20134.","journal-title":"Nature"},{"issue":"6","key":"2273_CR62","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.cmet.2013.11.001","volume":"18","author":"X Xu","year":"2013","unstructured":"Xu X, et al. Obesity activates a program of lysosomal-dependent lipid metabolism in adipose tissue macrophages independently of classic activation. Cell Metab. 2013;18(6):816\u201330.","journal-title":"Cell Metab"},{"issue":"3","key":"2273_CR63","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","volume":"178","author":"DA Jaitin","year":"2019","unstructured":"Jaitin DA, et al. Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent manner. Cell. 2019;178(3):686\u2013e69814.","journal-title":"Cell"},{"issue":"4","key":"2273_CR64","doi-asserted-by":"crossref","first-page":"E374","DOI":"10.1152\/ajpendo.00187.2014","volume":"307","author":"M Aouadi","year":"2014","unstructured":"Aouadi M, et al. Lipid storage by adipose tissue macrophages regulates systemic glucose tolerance. Am J Physiol Endocrinol Metab. 2014;307(4):E374\u201383.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2273_CR65","doi-asserted-by":"crossref","unstructured":"Lafuse WP, Wozniak DJ, Rajaram MVS. Role of Cardiac macrophages on Cardiac inflammation, fibrosis and tissue repair. Cells, 2020. 10(1).","DOI":"10.3390\/cells10010051"},{"key":"2273_CR66","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.yjmcc.2015.11.015","volume":"93","author":"M Hulsmans","year":"2016","unstructured":"Hulsmans M, Sam F, Nahrendorf M. Monocyte and macrophage contributions to cardiac remodeling. J Mol Cell Cardiol. 2016;93:149\u201355.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"2273_CR67","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41590-018-0272-2","volume":"20","author":"SA Dick","year":"2019","unstructured":"Dick SA, et al. Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction. Nat Immunol. 2019;20(1):29\u201339.","journal-title":"Nat Immunol"},{"key":"2273_CR68","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3389\/fimmu.2020.00639","volume":"11","author":"MJ Wagner","year":"2020","unstructured":"Wagner MJ, Khan M, Mohsin S. Healing the broken heart; the Immunomodulatory effects of Stem Cell Therapy. Front Immunol. 2020;11:639.","journal-title":"Front Immunol"},{"issue":"3","key":"2273_CR69","first-page":"187","volume":"38","author":"M Horckmans","year":"2017","unstructured":"Horckmans M, et al. Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. Eur Heart J. 2017;38(3):187\u201397.","journal-title":"Eur Heart J"},{"issue":"4","key":"2273_CR70","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/cvr\/cvx011","volume":"113","author":"G Frati","year":"2017","unstructured":"Frati G, et al. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. Cardiovasc Res. 2017;113(4):378\u201388.","journal-title":"Cardiovasc Res"},{"key":"2273_CR71","doi-asserted-by":"crossref","first-page":"118989","DOI":"10.1016\/j.lfs.2020.118989","volume":"268","author":"G Liu","year":"2021","unstructured":"Liu G, et al. The effect of mir-471-3p on macrophage polarization in the development of diabetic cardiomyopathy. Life Sci. 2021;268:118989.","journal-title":"Life Sci"},{"key":"2273_CR72","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3389\/fphys.2020.00694","volume":"11","author":"M Sharifi-Rad","year":"2020","unstructured":"Sharifi-Rad M, et al. Lifestyle, oxidative stress, and antioxidants: back and forth in the pathophysiology of Chronic diseases. Front Physiol. 2020;11:694.","journal-title":"Front Physiol"},{"issue":"3","key":"2273_CR73","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1385\/CT:1:3:181","volume":"1","author":"L Cai","year":"2001","unstructured":"Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol. 2001;1(3):181\u201393.","journal-title":"Cardiovasc Toxicol"},{"issue":"4","key":"2273_CR74","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/heartjnl-2017-311448","volume":"104","author":"AJ Wilson","year":"2018","unstructured":"Wilson AJ, et al. Reactive oxygen species signalling in the diabetic heart: emerging prospect for therapeutic targeting. Heart. 2018;104(4):293\u20139.","journal-title":"Heart"},{"issue":"6779","key":"2273_CR75","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/35008121","volume":"404","author":"T Nishikawa","year":"2000","unstructured":"Nishikawa T, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404(6779):787\u201390.","journal-title":"Nature"},{"issue":"6","key":"2273_CR76","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2337\/diabetes.54.6.1829","volume":"54","author":"L Cai","year":"2005","unstructured":"Cai L, et al. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes. 2005;54(6):1829\u201337.","journal-title":"Diabetes"},{"key":"2273_CR77","first-page":"p6673538","volume":"2021","author":"HZ Zhu","year":"2021","unstructured":"Zhu HZ, et al. Xiaoyaosan exerts therapeutic effects on the Colon of Chronic Restraint stress model rats via the regulation of Immunoinflammatory Activation Induced by the TLR4\/NLRP3 Inflammasome Signaling Pathway. Evid Based Complement Alternat Med. 2021;2021:p6673538.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"10","key":"2273_CR78","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1210\/en.2017-00294","volume":"158","author":"PB Pal","year":"2017","unstructured":"Pal PB, et al. Aldose Reductase mediates NLRP3 inflammasome-initiated Innate Immune Response in Hyperglycemia-Induced Thp1 monocytes and male mice. Endocrinology. 2017;158(10):3661\u201375.","journal-title":"Endocrinology"},{"key":"2273_CR79","doi-asserted-by":"crossref","first-page":"907757","DOI":"10.3389\/fendo.2022.907757","volume":"13","author":"ML Peng","year":"2022","unstructured":"Peng ML, et al. Signaling pathways related to oxidative stress in Diabetic Cardiomyopathy. Front Endocrinol (Lausanne). 2022;13:907757.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2273_CR80","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCRESAHA.110.223545","volume":"107","author":"F Giacco","year":"2010","unstructured":"Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058\u201370.","journal-title":"Circ Res"},{"issue":"6","key":"2273_CR81","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","volume":"54","author":"M Brownlee","year":"2005","unstructured":"Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615\u201325.","journal-title":"Diabetes"},{"issue":"13","key":"2273_CR82","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1016\/S0021-9258(17)36966-1","volume":"269","author":"SD Yan","year":"1994","unstructured":"Yan SD, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors\/binding proteins. J Biol Chem. 1994;269(13):9889\u201397.","journal-title":"J Biol Chem"},{"issue":"2","key":"2273_CR83","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.imbio.2018.11.010","volume":"224","author":"E Rendra","year":"2019","unstructured":"Rendra E, et al. Reactive oxygen species (ROS) in macrophage activation and function in diabetes. Immunobiology. 2019;224(2):242\u201353.","journal-title":"Immunobiology"},{"issue":"9","key":"2273_CR84","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","volume":"364","author":"HC Gerstein","year":"2011","unstructured":"Gerstein HC, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818\u201328.","journal-title":"N Engl J Med"},{"issue":"15","key":"2273_CR85","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJMe0807625","volume":"359","author":"J Chalmers","year":"2008","unstructured":"Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med. 2008;359(15):1618\u201320.","journal-title":"N Engl J Med"},{"issue":"3","key":"2273_CR86","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41590-023-01428-x","volume":"24","author":"T Wang","year":"2023","unstructured":"Wang T, et al. Influenza-trained mucosal-resident alveolar macrophages confer long-term antitumor immunity in the lungs. Nat Immunol. 2023;24(3):423\u201338.","journal-title":"Nat Immunol"},{"issue":"6","key":"2273_CR87","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","volume":"20","author":"MG Netea","year":"2020","unstructured":"Netea MG, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20(6):375\u201388.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"2273_CR88","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.120.046464","volume":"144","author":"L Edgar","year":"2021","unstructured":"Edgar L, et al. Hyperglycemia induces trained immunity in macrophages and their precursors and promotes atherosclerosis. Circulation. 2021;144(12):961\u201382.","journal-title":"Circulation"},{"issue":"1","key":"2273_CR89","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1079\/BJN2002763","volume":"89","author":"IS Wood","year":"2003","unstructured":"Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr. 2003;89(1):3\u20139.","journal-title":"Br J Nutr"},{"key":"2273_CR90","doi-asserted-by":"crossref","first-page":"836849","DOI":"10.3389\/fphar.2022.836849","volume":"13","author":"L Xie","year":"2022","unstructured":"Xie L, et al. Emerging roles of Sodium glucose cotransporter 2 (SGLT-2) inhibitors in Diabetic Cardiovascular diseases: focusing on immunity, inflammation and metabolism. Front Pharmacol. 2022;13:836849.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2273_CR91","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4093\/dmj.2021.0280","volume":"46","author":"SH Lee","year":"2022","unstructured":"Lee SH, Park SY, Choi CS. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J. 2022;46(1):15\u201337.","journal-title":"Diabetes Metab J"},{"key":"2273_CR92","doi-asserted-by":"crossref","first-page":"749010","DOI":"10.3389\/fendo.2021.749010","volume":"12","author":"J Shaffner","year":"2021","unstructured":"Shaffner J, et al. Therapeutic targeting of SGLT2: a new era in the treatment of Diabetes and Diabetic kidney disease. Front Endocrinol (Lausanne). 2021;12:749010.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"22","key":"2273_CR93","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","volume":"139","author":"ET Kato","year":"2019","unstructured":"Kato ET, et al. Effect of Dapagliflozin on Heart failure and mortality in type 2 diabetes Mellitus. Circulation. 2019;139(22):2528\u201336.","journal-title":"Circulation"},{"issue":"22","key":"2273_CR94","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","volume":"139","author":"RHM Furtado","year":"2019","unstructured":"Furtado RHM, et al. Dapagliflozin and Cardiovascular outcomes in patients with type 2 diabetes Mellitus and previous myocardial infarction. Circulation. 2019;139(22):2516\u201327.","journal-title":"Circulation"},{"key":"2273_CR95","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","volume":"104","author":"TM Lee","year":"2017","unstructured":"Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298\u2013310.","journal-title":"Free Radic Biol Med"},{"key":"2273_CR96","doi-asserted-by":"crossref","unstructured":"Iannantuoni F et al. The SGLT2 inhibitor Empagliflozin ameliorates the Inflammatory Profile in type 2 Diabetic patients and promotes an antioxidant response in leukocytes. J Clin Med, 2019. 8(11).","DOI":"10.3390\/jcm8111814"},{"issue":"1","key":"2273_CR97","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim SR, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11(1):2127.","journal-title":"Nat Commun"},{"issue":"12","key":"2273_CR98","doi-asserted-by":"crossref","first-page":"101334","DOI":"10.1016\/j.xcrm.2023.101334","volume":"4","author":"Q Wu","year":"2023","unstructured":"Wu Q, et al. Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2. Cell Rep Med. 2023;4(12):101334.","journal-title":"Cell Rep Med"},{"key":"2273_CR99","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","volume":"20","author":"L Xu","year":"2017","unstructured":"Xu L, et al. SGLT2 inhibition by Empagliflozin Promotes Fat Utilization and Browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in Diet-induced obese mice. EBioMedicine. 2017;20:137\u201349.","journal-title":"EBioMedicine"},{"issue":"2","key":"2273_CR100","first-page":"121","volume":"7","author":"L Xu","year":"2018","unstructured":"Xu L, Ota T. Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: focus on fat browning and macrophage polarization. Adipocyte. 2018;7(2):121\u20138.","journal-title":"Adipocyte"},{"issue":"6","key":"2273_CR101","doi-asserted-by":"crossref","first-page":"e100777","DOI":"10.1371\/journal.pone.0100777","volume":"9","author":"N Terami","year":"2014","unstructured":"Terami N, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice. PLoS ONE. 2014;9(6):e100777.","journal-title":"PLoS ONE"},{"issue":"11","key":"2273_CR102","doi-asserted-by":"crossref","first-page":"e112394","DOI":"10.1371\/journal.pone.0112394","volume":"9","author":"M Oelze","year":"2014","unstructured":"Oelze M, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the Streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS ONE. 2014;9(11):e112394.","journal-title":"PLoS ONE"},{"issue":"21","key":"2273_CR103","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"4","key":"2273_CR104","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, et al. Dapagliflozin and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"22","key":"2273_CR105","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, et al. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"2273_CR106","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, et al. Canagliflozin and Cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"2","key":"2273_CR107","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","volume":"31","author":"Y Ye","year":"2017","unstructured":"Ye Y, et al. SGLT-2 inhibition with Dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the Development of Diabetic Cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with Saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther. 2017;31(2):119\u201332.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"2273_CR108","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.metabol.2015.10.010","volume":"65","author":"M Kern","year":"2016","unstructured":"Kern M, et al. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db\/db mice both as monotherapy and in combination with linagliptin. Metabolism. 2016;65(2):114\u201323.","journal-title":"Metabolism"},{"issue":"1","key":"2273_CR109","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","volume":"16","author":"J Habibi","year":"2017","unstructured":"Habibi J, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16(1):9.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2273_CR110","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2337\/diab.43.4.535","volume":"43","author":"C Orskov","year":"1994","unstructured":"Orskov C, et al. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43(4):535\u20139.","journal-title":"Diabetes"},{"issue":"Suppl 3","key":"2273_CR111","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.2337\/diabetes.51.2007.S434","volume":"51","author":"PE MacDonald","year":"2002","unstructured":"MacDonald PE, et al. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes. 2002;51(Suppl 3):S434\u201342.","journal-title":"Diabetes"},{"key":"2273_CR112","doi-asserted-by":"crossref","first-page":"105782","DOI":"10.1016\/j.phrs.2021.105782","volume":"171","author":"E Lazzaroni","year":"2021","unstructured":"Lazzaroni E, et al. Anti-diabetic drugs and weight loss in patients with type 2 diabetes. Pharmacol Res. 2021;171:105782.","journal-title":"Pharmacol Res"},{"issue":"10","key":"2273_CR113","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2273_CR114","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","volume":"6","author":"MA Bethel","year":"2018","unstructured":"Bethel MA, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105\u201313.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2273_CR115","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.2337\/dci22-0014","volume":"45","author":"R Pop-Busui","year":"2022","unstructured":"Pop-Busui R, et al. Heart failure: an underappreciated complication of diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care. 2022;45(7):1670\u201390.","journal-title":"Diabetes Care"},{"issue":"1","key":"2273_CR116","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.cjca.2020.02.098","volume":"37","author":"M Almutairi","year":"2021","unstructured":"Almutairi M, et al. The GLP-1 receptor agonist Liraglutide increases myocardial glucose oxidation Rates via Indirect mechanisms and mitigates Experimental Diabetic Cardiomyopathy. Can J Cardiol. 2021;37(1):140\u201350.","journal-title":"Can J Cardiol"},{"key":"2273_CR117","doi-asserted-by":"crossref","unstructured":"Trang NN et al. Empagliflozin and Liraglutide differentially modulate Cardiac Metabolism in Diabetic Cardiomyopathy in rats. Int J Mol Sci, 2021. 22(3).","DOI":"10.3390\/ijms22031177"},{"key":"2273_CR118","doi-asserted-by":"crossref","first-page":"114209","DOI":"10.1016\/j.bcp.2020.114209","volume":"182","author":"P Qian","year":"2020","unstructured":"Qian P, et al. A novel oral glucagon-like peptide 1 receptor agonist protects against diabetic cardiomyopathy via alleviating cardiac lipotoxicity induced mitochondria dysfunction. Biochem Pharmacol. 2020;182:114209.","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"2273_CR119","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.7150\/ijbs.59965","volume":"17","author":"X Ma","year":"2021","unstructured":"Ma X, et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021;17(8):2050\u201368.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"2273_CR120","first-page":"3573","volume":"17","author":"S Wan","year":"2019","unstructured":"Wan S, Sun H. Glucagon-like peptide-1 modulates RAW264.7 macrophage polarization by interfering with the JNK\/STAT3 signaling pathway. Exp Ther Med. 2019;17(5):3573\u20139.","journal-title":"Exp Ther Med"},{"issue":"5","key":"2273_CR121","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1159\/000485776","volume":"44","author":"N Wang","year":"2017","unstructured":"Wang N, et al. Exendin-4 induces bone marrow stromal cells Migration through Bone Marrow-Derived macrophages polarization via PKA-STAT3 signaling pathway. Cell Physiol Biochem. 2017;44(5):1696\u2013714.","journal-title":"Cell Physiol Biochem"},{"key":"2273_CR122","first-page":"p5568159","volume":"2021","author":"L Yang","year":"2021","unstructured":"Yang L, et al. Effect of GLP-1\/GLP-1R on the polarization of macrophages in the occurrence and development of atherosclerosis. Mediators Inflamm. 2021;2021:p5568159.","journal-title":"Mediators Inflamm"},{"issue":"1","key":"2273_CR123","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1172\/JCI24335","volume":"116","author":"SP Weisberg","year":"2006","unstructured":"Weisberg SP, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest. 2006;116(1):115\u201324.","journal-title":"J Clin Invest"},{"issue":"8","key":"2273_CR124","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/nm.2001","volume":"15","author":"S Winer","year":"2009","unstructured":"Winer S, et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med. 2009;15(8):921\u20139.","journal-title":"Nat Med"},{"issue":"9","key":"2273_CR125","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s00125-012-2592-3","volume":"55","author":"YS Lee","year":"2012","unstructured":"Lee YS, et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia. 2012;55(9):2456\u201368.","journal-title":"Diabetologia"},{"issue":"1","key":"2273_CR126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00395-015-0518-1","volume":"111","author":"M Tate","year":"2016","unstructured":"Tate M, et al. Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages. Basic Res Cardiol. 2016;111(1):1.","journal-title":"Basic Res Cardiol"},{"issue":"2","key":"2273_CR127","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(19)30423-1","volume":"8","author":"HC Gerstein","year":"2020","unstructured":"Gerstein HC, et al. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes Endocrinol. 2020;8(2):106\u201314.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2273_CR128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01183-5","volume":"20","author":"A Tuttolomondo","year":"2021","unstructured":"Tuttolomondo A, et al. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial. Cardiovasc Diabetol. 2021;20(1):1.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2273_CR129","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Liraglutide and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"9","key":"2273_CR130","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, et al. Oral Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"9","key":"2273_CR131","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/STROKEAHA.121.037775","volume":"53","author":"WD Strain","year":"2022","unstructured":"Strain WD, et al. Effects of Semaglutide on Stroke subtypes in type 2 diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6. Stroke. 2022;53(9):2749\u201357.","journal-title":"Stroke"},{"issue":"10","key":"2273_CR132","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, et al. Cardiovascular and renal outcomes with Efpeglenatide in Type 2 diabetes. N Engl J Med. 2021;385(10):896\u2013907.","journal-title":"N Engl J Med"},{"issue":"10157","key":"2273_CR133","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"8","key":"2273_CR134","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1038\/nutd.2016.37","volume":"6","author":"MP van der Aa","year":"2016","unstructured":"van der Aa MP, et al. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutr Diabetes. 2016;6(8):e228.","journal-title":"Nutr Diabetes"},{"issue":"4 Pt 2","key":"2273_CR135","first-page":"s628","volume":"29","author":"R Giannarelli","year":"2003","unstructured":"Giannarelli R, et al. Reducing insulin resistance with metformin: the evidence today. Diabetes Metab. 2003;29(4 Pt 2):s628\u201335.","journal-title":"Diabetes Metab"},{"issue":"3","key":"2273_CR136","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cvr\/cvq066","volume":"87","author":"H Xiao","year":"2010","unstructured":"Xiao H, et al. Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovasc Res. 2010;87(3):504\u201313.","journal-title":"Cardiovasc Res"},{"key":"2273_CR137","doi-asserted-by":"crossref","first-page":"i3477","DOI":"10.1136\/bmj.i3477","volume":"354","author":"J Hippisley-Cox","year":"2016","unstructured":"Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. BMJ. 2016;354:i3477.","journal-title":"BMJ"},{"issue":"3","key":"2273_CR138","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/M16-1901","volume":"166","author":"MJ Crowley","year":"2017","unstructured":"Crowley MJ, et al. Clinical outcomes of Metformin Use in populations with chronic kidney disease, congestive heart failure, or Chronic Liver Disease: a systematic review. Ann Intern Med. 2017;166(3):191\u2013200.","journal-title":"Ann Intern Med"},{"key":"2273_CR139","doi-asserted-by":"crossref","unstructured":"Nassif RM et al. Metformin inhibits ROS production by human M2 macrophages via the activation of AMPK. Biomedicines, 2022. 10(2).","DOI":"10.3390\/biomedicines10020319"},{"key":"2273_CR140","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez ML et al. Polymers and Bioactive compounds with a macrophage modulation effect for the Rational Design of Hydrogels for skin regeneration. Pharmaceutics, 2023. 15(6).","DOI":"10.3390\/pharmaceutics15061655"},{"key":"2273_CR141","doi-asserted-by":"crossref","unstructured":"Das B et al. Promise of the NLRP3 inflammasome inhibitors in in vivo Disease models. Molecules, 2021. 26(16).","DOI":"10.3390\/molecules26164996"},{"issue":"20","key":"2273_CR142","doi-asserted-by":"crossref","first-page":"8436","DOI":"10.1074\/jbc.M116.769380","volume":"292","author":"T Horiuchi","year":"2017","unstructured":"Horiuchi T, et al. Metformin directly binds the alarmin HMGB1 and inhibits its proinflammatory activity. J Biol Chem. 2017;292(20):8436\u201346.","journal-title":"J Biol Chem"},{"key":"2273_CR143","doi-asserted-by":"crossref","first-page":"682853","DOI":"10.3389\/fimmu.2021.682853","volume":"12","author":"X Feng","year":"2021","unstructured":"Feng X, et al. Metformin, macrophage dysfunction and atherosclerosis. Front Immunol. 2021;12:682853.","journal-title":"Front Immunol"},{"key":"2273_CR144","doi-asserted-by":"crossref","first-page":"110912","DOI":"10.1016\/j.biopha.2020.110912","volume":"133","author":"C Guo","year":"2021","unstructured":"Guo C, Liu J, Li H. Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats. Biomed Pharmacother. 2021;133:110912.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2273_CR145","doi-asserted-by":"crossref","first-page":"7471","DOI":"10.1038\/s41467-023-42277-4","volume":"14","author":"M Cort\u00e9s","year":"2023","unstructured":"Cort\u00e9s M, et al. Inflammatory macrophages reprogram to immunosuppression by reducing mitochondrial translation. Nat Commun. 2023;14(1):7471.","journal-title":"Nat Commun"},{"issue":"2","key":"2273_CR146","doi-asserted-by":"crossref","first-page":"e2461","DOI":"10.1016\/j.ajog.2020.01.054","volume":"223","author":"O Panagiotopoulou","year":"2020","unstructured":"Panagiotopoulou O, et al. Metformin use in obese mothers is associated with improved cardiovascular profile in the offspring. Am J Obstet Gynecol. 2020;223(2):246.e1\u201310.","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"2273_CR147","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/dom.14350","volume":"23","author":"JG Timmons","year":"2021","unstructured":"Timmons JG, et al. Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: the REMOVAL trial. Diabetes Obes Metab. 2021;23(6):1371\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2273_CR148","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","volume":"6","author":"DT Eurich","year":"2013","unstructured":"Eurich DT, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6(3):395\u2013402.","journal-title":"Circ Heart Fail"},{"issue":"5","key":"2273_CR149","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1111\/jcmm.14834","volume":"24","author":"S Bhansali","year":"2020","unstructured":"Bhansali S, et al. Metformin upregulates mitophagy in patients with T2DM: a randomized placebo-controlled study. J Cell Mol Med. 2020;24(5):2832\u201346.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"2273_CR150","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.7150\/ijbs.29680","volume":"15","author":"F Yang","year":"2019","unstructured":"Yang F, et al. Metformin inhibits the NLRP3 Inflammasome via AMPK\/mTOR-dependent effects in Diabetic Cardiomyopathy. Int J Biol Sci. 2019;15(5):1010\u20139.","journal-title":"Int J Biol Sci"},{"issue":"7","key":"2273_CR151","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/j.1476-5381.2010.01126.x","volume":"162","author":"K Tsoyi","year":"2011","unstructured":"Tsoyi K, et al. Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice. Br J Pharmacol. 2011;162(7):1498\u2013508.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"2273_CR152","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.lfs.2005.12.036","volume":"79","author":"F Fiordaliso","year":"2006","unstructured":"Fiordaliso F, et al. Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sci. 2006;79(2):121\u20139.","journal-title":"Life Sci"},{"issue":"3","key":"2273_CR153","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/01.fjc.0000245405.41317.60","volume":"48","author":"H Matsusaka","year":"2006","unstructured":"Matsusaka H, et al. Angiotensin II type 1 receptor blocker attenuates exacerbated left ventricular remodeling and failure in diabetes-associated myocardial infarction. J Cardiovasc Pharmacol. 2006;48(3):95\u2013102.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"2273_CR154","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00399-021-00770-7","volume":"32","author":"T Wichter","year":"2021","unstructured":"Wichter T, et al. Pregnancy in arrhythmogenic cardiomyopathy. Herzschrittmacherther Elektrophysiol. 2021;32(2):186\u201398.","journal-title":"Herzschrittmacherther Elektrophysiol"},{"issue":"4","key":"2273_CR155","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1161\/01.HYP.37.4.1053","volume":"37","author":"JR Sowers","year":"2001","unstructured":"Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37(4):1053\u20139.","journal-title":"Hypertension"},{"issue":"1\u20132","key":"2273_CR156","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11010-009-0098-1","volume":"330","author":"J Yang","year":"2009","unstructured":"Yang J, et al. Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4\/NF-kappaB signaling pathway. Mol Cell Biochem. 2009;330(1\u20132):39\u201346.","journal-title":"Mol Cell Biochem"},{"issue":"2","key":"2273_CR157","doi-asserted-by":"crossref","first-page":"H912","DOI":"10.1152\/ajpheart.00824.2006","volume":"292","author":"N Yaras","year":"2007","unstructured":"Yaras N, et al. Restoration of diabetes-induced abnormal local Ca2\u2009+\u2009release in cardiomyocytes by angiotensin II receptor blockade. Am J Physiol Heart Circ Physiol. 2007;292(2):H912\u201320.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"2273_CR158","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","volume":"119","author":"SD Solomon","year":"2009","unstructured":"Solomon SD, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119(4):530\u20137.","journal-title":"Circulation"},{"issue":"2","key":"2273_CR159","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/eurjhf\/hfr125","volume":"14","author":"AM Shah","year":"2012","unstructured":"Shah AM, et al. Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. Eur J Heart Fail. 2012;14(2):185\u201392.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"2273_CR160","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/HYPERTENSIONAHA.107.091058","volume":"50","author":"M Nagase","year":"2007","unstructured":"Nagase M, et al. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension. 2007;50(5):877\u201383.","journal-title":"Hypertension"},{"issue":"2","key":"2273_CR161","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijcard.2008.04.059","volume":"130","author":"JM Lambert","year":"2008","unstructured":"Lambert JM, Lopez EF, Lindsey ML. Macrophage roles following myocardial infarction. Int J Cardiol. 2008;130(2):147\u201358.","journal-title":"Int J Cardiol"},{"issue":"1","key":"2273_CR162","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12933-022-01690-7","volume":"21","author":"AA Mansour","year":"2022","unstructured":"Mansour AA, et al. The interplay of galectins-1, -3, and\u2013\u20099 in the immune-inflammatory response underlying cardiovascular and metabolic disease. Cardiovasc Diabetol. 2022;21(1):253.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"2273_CR163","first-page":"1058","volume":"4","author":"M Camici","year":"2012","unstructured":"Camici M, et al. Obesity-related glomerulopathy and podocyte injury: a mini review. Front Biosci (Elite Ed). 2012;4(3):1058\u201370.","journal-title":"Front Biosci (Elite Ed)"},{"issue":"9153","key":"2273_CR164","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"353","author":"L Hansson","year":"1999","unstructured":"Hansson L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353(9153):611\u20136.","journal-title":"Lancet"},{"issue":"3","key":"2273_CR165","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145\u201353.","journal-title":"N Engl J Med"},{"issue":"3","key":"2273_CR166","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ki.2012.74","volume":"82","author":"HJ Lambers Heerspink","year":"2012","unstructured":"Lambers Heerspink HJ, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int. 2012;82(3):330\u20137.","journal-title":"Kidney Int"},{"issue":"25","key":"2273_CR167","doi-asserted-by":"crossref","first-page":"6366","DOI":"10.1002\/anie.201301924","volume":"52","author":"RJ Lefkowitz","year":"2013","unstructured":"Lefkowitz RJ. A brief history of G-protein coupled receptors (Nobel lecture). Angew Chem Int Ed Engl. 2013;52(25):6366\u201378.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"6","key":"2273_CR168","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/0006-2952(94)90141-4","volume":"48","author":"G Milligan","year":"1994","unstructured":"Milligan G, Svoboda P, Brown CM. Why are there so many adrenoceptor subtypes? Biochem Pharmacol. 1994;48(6):1059\u201371.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2273_CR169","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.tpj.6500393","volume":"7","author":"MR Taylor","year":"2007","unstructured":"Taylor MR. Pharmacogenetics of the human beta-adrenergic receptors. Pharmacogenomics J. 2007;7(1):29\u201337.","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"2273_CR170","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/13543776.2021.1865312","volume":"31","author":"G Xing","year":"2021","unstructured":"Xing G, et al. Recent progress in the development of \u03b22 adrenergic receptor agonists: a patent review (2015\u20132020). Expert Opin Ther Pat. 2021;31(3):239\u201346.","journal-title":"Expert Opin Ther Pat"},{"issue":"8","key":"2273_CR171","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2174\/1871530319666190206124520","volume":"19","author":"E Ortega","year":"2019","unstructured":"Ortega E, G\u00e1lvez I, Mart\u00edn-Cordero L. Adrenergic regulation of macrophage-mediated Innate\/Inflammatory responses in obesity and Exercise in this Condition: role of \u03b22 adrenergic receptors. Endocr Metab Immune Disord Drug Targets. 2019;19(8):1089\u201399.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"1","key":"2273_CR172","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.kint.2017.02.013","volume":"92","author":"H Noh","year":"2017","unstructured":"Noh H, et al. Beta 2-adrenergic receptor agonists are novel regulators of macrophage activation in diabetic renal and cardiovascular complications. Kidney Int. 2017;92(1):101\u201313.","journal-title":"Kidney Int"},{"key":"2273_CR173","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2147\/DDDT.S149298","volume":"12","author":"H Zhang","year":"2018","unstructured":"Zhang H, et al. Renal-protective effect of thalidomide in streptozotocin-induced diabetic rats through anti-inflammatory pathway. Drug Des Devel Ther. 2018;12:89\u201398.","journal-title":"Drug Des Devel Ther"},{"issue":"52","key":"2273_CR174","doi-asserted-by":"crossref","first-page":"15126","DOI":"10.1073\/pnas.1611023114","volume":"113","author":"LA Grisanti","year":"2016","unstructured":"Grisanti LA, et al. \u03b22-Adrenergic receptor-dependent chemokine receptor 2 expression regulates leukocyte recruitment to the heart following acute injury. Proc Natl Acad Sci U S A. 2016;113(52):15126\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2273_CR175","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/01.CIR.99.1.65","volume":"99","author":"A Kaumann","year":"1999","unstructured":"Kaumann A, et al. Activation of beta2-adrenergic receptors hastens relaxation and mediates phosphorylation of phospholamban, troponin I, and C-protein in ventricular myocardium from patients with terminal heart failure. Circulation. 1999;99(1):65\u201372.","journal-title":"Circulation"},{"issue":"14","key":"2273_CR176","doi-asserted-by":"crossref","first-page":"14300","DOI":"10.18632\/aging.103469","volume":"12","author":"J Gong","year":"2020","unstructured":"Gong J, et al. Caveolin-3 protects diabetic hearts from acute myocardial infarction\/reperfusion injury through \u03b22AR, cAMP\/PKA, and BDNF\/TrkB signaling pathways. Aging. 2020;12(14):14300\u201313.","journal-title":"Aging"},{"issue":"3","key":"2273_CR177","doi-asserted-by":"crossref","first-page":"E619","DOI":"10.1152\/ajpendo.00324.2020","volume":"320","author":"SMM van Beek","year":"2021","unstructured":"van Beek SMM, et al. Prolonged \u03b2(2)-adrenergic agonist treatment improves glucose homeostasis in diet-induced obese UCP1(-\/-) mice. Am J Physiol Endocrinol Metab. 2021;320(3):E619\u201328.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"10","key":"2273_CR178","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41581-022-00608-6","volume":"18","author":"N Mahtal","year":"2022","unstructured":"Mahtal N, et al. MicroRNAs in kidney injury and disease. Nat Rev Nephrol. 2022;18(10):643\u201362.","journal-title":"Nat Rev Nephrol"},{"key":"2273_CR179","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12935-017-0398-6","volume":"17","author":"X Guo","year":"2017","unstructured":"Guo X, et al. miR-335 negatively regulates osteosarcoma stem cell-like properties by targeting POU5F1. Cancer Cell Int. 2017;17:29.","journal-title":"Cancer Cell Int"},{"key":"2273_CR180","doi-asserted-by":"crossref","first-page":"738140","DOI":"10.3389\/fphys.2021.738140","volume":"12","author":"I Duroux-Richard","year":"2021","unstructured":"Duroux-Richard I, Apparailly F, Khoury M. Mitochondrial MicroRNAs contribute to Macrophage Immune functions including differentiation, polarization, and activation. Front Physiol. 2021;12:738140.","journal-title":"Front Physiol"},{"key":"2273_CR181","doi-asserted-by":"crossref","unstructured":"Zhong Y, Yi C. MicroRNA-720 suppresses M2 macrophage polarization by targeting GATA3. Biosci Rep, 2016. 36(4).","DOI":"10.1042\/BSR20160105"},{"issue":"3","key":"2273_CR182","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4049\/jimmunol.1402088","volume":"194","author":"H Ying","year":"2015","unstructured":"Ying H, et al. MiR-127 modulates macrophage polarization and promotes lung inflammation and injury by activating the JNK pathway. J Immunol. 2015;194(3):1239\u201351.","journal-title":"J Immunol"},{"issue":"11","key":"2273_CR183","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1172\/JCI61716","volume":"122","author":"M Nazari-Jahantigh","year":"2012","unstructured":"Nazari-Jahantigh M, et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest. 2012;122(11):4190\u2013202.","journal-title":"J Clin Invest"},{"key":"2273_CR184","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.molimm.2016.08.007","volume":"77","author":"D Li","year":"2016","unstructured":"Li D, et al. MiR-146a modulates macrophage polarization in systemic juvenile idiopathic arthritis by targeting INHBA. Mol Immunol. 2016;77:205\u201312.","journal-title":"Mol Immunol"},{"issue":"1","key":"2273_CR185","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.bbrc.2009.07.147","volume":"388","author":"JP Mu\u00f1oz","year":"2009","unstructured":"Mu\u00f1oz JP, et al. The transcription factor MEF2C mediates cardiomyocyte hypertrophy induced by IGF-1 signaling. Biochem Biophys Res Commun. 2009;388(1):155\u201360.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"2273_CR186","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcjd.2013.07.003","volume":"37","author":"MA Ruiz","year":"2013","unstructured":"Ruiz MA, Chakrabarti S. MicroRNAs: the underlying mediators of pathogenetic processes in vascular complications of diabetes. Can J Diabetes. 2013;37(5):339\u201344.","journal-title":"Can J Diabetes"},{"key":"2273_CR187","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1475-2840-13-68","volume":"13","author":"A Moore","year":"2014","unstructured":"Moore A, et al. Rapid onset of cardiomyopathy in STZ-induced female diabetic mice involves the downregulation of pro-survival Pim-1. Cardiovasc Diabetol. 2014;13:68.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"2273_CR188","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCRESAHA.116.304707","volume":"116","author":"Y Kuwabara","year":"2015","unstructured":"Kuwabara Y, et al. MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1\/AMPK pathway. Circ Res. 2015;116(2):279\u201388.","journal-title":"Circ Res"},{"issue":"12","key":"2273_CR189","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.cjca.2014.07.747","volume":"30","author":"S Liu","year":"2014","unstructured":"Liu S, et al. Micro-RNA 21Targets dual specific phosphatase 8 to promote collagen synthesis in high glucose-treated primary cardiac fibroblasts. Can J Cardiol. 2014;30(12):1689\u201399.","journal-title":"Can J Cardiol"},{"issue":"3","key":"2273_CR190","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s12013-013-9672-y","volume":"67","author":"SS Yildirim","year":"2013","unstructured":"Yildirim SS, et al. Relationship between downregulation of miRNAs and increase of oxidative stress in the development of diabetic cardiac dysfunction: junctin as a target protein of miR-1. Cell Biochem Biophys. 2013;67(3):1397\u2013408.","journal-title":"Cell Biochem Biophys"},{"key":"2273_CR191","first-page":"p4851214","volume":"2019","author":"P Wang","year":"2019","unstructured":"Wang P, et al. miR-657 promotes macrophage polarization toward M1 by targeting FAM46C in gestational diabetes Mellitus. Mediators Inflamm. 2019;2019:p4851214.","journal-title":"Mediators Inflamm"},{"issue":"23","key":"2273_CR192","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1161\/CIRCULATIONAHA.111.087817","volume":"125","author":"G Zhuang","year":"2012","unstructured":"Zhuang G, et al. A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation. Circulation. 2012;125(23):2892\u2013903.","journal-title":"Circulation"},{"key":"2273_CR193","doi-asserted-by":"crossref","first-page":"576516","DOI":"10.3389\/fimmu.2020.576516","volume":"11","author":"S Fitzsimons","year":"2020","unstructured":"Fitzsimons S, et al. microRNA-155 is decreased during atherosclerosis regression and is increased in urinary extracellular vesicles during atherosclerosis progression. Front Immunol. 2020;11:576516.","journal-title":"Front Immunol"},{"key":"2273_CR194","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.2147\/IJN.S138400","volume":"12","author":"C Jia","year":"2017","unstructured":"Jia C, et al. Gold nanoparticle-based miR155 antagonist macrophage delivery restores the cardiac function in ovariectomized diabetic mouse model. Int J Nanomed. 2017;12:4963\u201379.","journal-title":"Int J Nanomed"},{"issue":"6","key":"2273_CR195","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.ymthe.2022.03.008","volume":"30","author":"TA Phu","year":"2022","unstructured":"Phu TA, et al. IL-4 polarized human macrophage exosomes control cardiometabolic inflammation and diabetes in obesity. Mol Ther. 2022;30(6):2274\u201397.","journal-title":"Mol Ther"},{"issue":"2","key":"2273_CR196","doi-asserted-by":"crossref","first-page":"107881","DOI":"10.1016\/j.celrep.2020.107881","volume":"32","author":"L Bouchareychas","year":"2020","unstructured":"Bouchareychas L, et al. Macrophage exosomes resolve atherosclerosis by regulating hematopoiesis and inflammation via MicroRNA Cargo. Cell Rep. 2020;32(2):107881.","journal-title":"Cell Rep"},{"issue":"12","key":"2273_CR197","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1007\/s00125-023-05992-7","volume":"66","author":"JM Li","year":"2023","unstructured":"Li JM, et al. Lipotoxicity-polarised macrophage-derived exosomes regulate mitochondrial fitness through Miro1-mediated mitophagy inhibition and contribute to type 2 diabetes development in mice. Diabetologia. 2023;66(12):2368\u201386.","journal-title":"Diabetologia"},{"key":"2273_CR198","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.molimm.2018.02.006","volume":"95","author":"J Sun","year":"2018","unstructured":"Sun J, et al. miR-330-5p\/Tim-3 axis regulates macrophage M2 polarization and insulin resistance in diabetes mice. Mol Immunol. 2018;95:107\u201313.","journal-title":"Mol Immunol"},{"issue":"1","key":"2273_CR199","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s12967-022-03502-8","volume":"20","author":"J Cao","year":"2022","unstructured":"Cao J, et al. Extracellular vesicle miR-32 derived from macrophage promotes arterial calcification in mice with type 2 diabetes via inhibiting VSMC autophagy. J Transl Med. 2022;20(1):307.","journal-title":"J Transl Med"},{"issue":"12","key":"2273_CR200","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1161\/ATVBAHA.119.312707","volume":"39","author":"YJ Chang","year":"2019","unstructured":"Chang YJ, et al. Extracellular MicroRNA-92a mediates endothelial cell-macrophage communication. Arterioscler Thromb Vasc Biol. 2019;39(12):2492\u2013504.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2273_CR201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2016.10.004","volume":"180","author":"M Zhang","year":"2016","unstructured":"Zhang M, et al. MiR-130b promotes obesity associated adipose tissue inflammation and insulin resistance in diabetes mice through alleviating M2 macrophage polarization via repression of PPAR-\u03b3. Immunol Lett. 2016;180:1\u20138.","journal-title":"Immunol Lett"},{"key":"2273_CR202","doi-asserted-by":"crossref","first-page":"36207","DOI":"10.1038\/srep36207","volume":"6","author":"S Suresh Babu","year":"2016","unstructured":"Suresh Babu S, et al. MicroRNA-126 overexpression rescues diabetes-induced impairment in efferocytosis of apoptotic cardiomyocytes. Sci Rep. 2016;6:36207.","journal-title":"Sci Rep"},{"issue":"16","key":"2273_CR203","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1007\/s00018-014-1579-2","volume":"71","author":"D Acu\u00f1a-Castroviejo","year":"2014","unstructured":"Acu\u00f1a-Castroviejo D, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci. 2014;71(16):2997\u20133025.","journal-title":"Cell Mol Life Sci"},{"issue":"sup1","key":"2273_CR204","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1080\/10408398.2018.1487927","volume":"59","author":"SM Nabavi","year":"2019","unstructured":"Nabavi SM, et al. Anti-inflammatory effects of melatonin: a mechanistic review. Crit Rev Food Sci Nutr. 2019;59(sup1):S4\u201316.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"2","key":"2273_CR205","first-page":"159","volume":"28","author":"K Stebelov\u00e1","year":"2007","unstructured":"Stebelov\u00e1 K, Herichov\u00e1 I, Zeman M. Diabetes induces changes in melatonin concentrations in peripheral tissues of rat. Neuro Endocrinol Lett. 2007;28(2):159\u201365.","journal-title":"Neuro Endocrinol Lett"},{"issue":"9002","key":"2273_CR206","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(96)91246-5","volume":"347","author":"P Fiorina","year":"1996","unstructured":"Fiorina P, et al. Impaired nocturnal melatonin excretion and changes of immunological status in ischaemic stroke patients. Lancet. 1996;347(9002):692\u20133.","journal-title":"Lancet"},{"issue":"2","key":"2273_CR207","doi-asserted-by":"crossref","first-page":"e12847","DOI":"10.1111\/jpi.12847","volume":"74","author":"J Maity","year":"2023","unstructured":"Maity J, et al. Melatonin ameliorates myocardial infarction in obese diabetic individuals: the possible involvement of macrophage apoptotic factors. J Pineal Res. 2023;74(2):e12847.","journal-title":"J Pineal Res"}],"updated-by":[{"DOI":"10.1186\/s12933-024-02300-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000}}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02273-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02273-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02273-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T09:05:14Z","timestamp":1719824714000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02273-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":207,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2273"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02273-4","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"12 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12933-024-02300-4","URL":"https:\/\/doi.org\/10.1186\/s12933-024-02300-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}